Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 245Carcinoma, Non-Small-Cell Lung 225Prostatic Neoplasms 113Neoplasms 104Multiple Myeloma 90Neoplasm Metastasis 75Colorectal Neoplasms 73Parkinson Disease 4, Autosomal Dominant Lewy Body 69Lung Neoplasms 66Ovarian Neoplasms 61Leukemia, Myeloid, Acute 50Carcinoma, Hepatocellular 47Melanoma 46Leukemia, Lymphocytic, Chronic, B-Cell 44Carcinoma, Renal Cell 43Urinary Bladder Neoplasms 41Stomach Neoplasms 41Squamous Cell Carcinoma of Head and Neck 41Triple Negative Breast Neoplasms 40Recurrence 40Brain Neoplasms 40Myasthenia Gravis 37Small Cell Lung Carcinoma 35Lymphoma, Follicular 35Nasopharyngeal Carcinoma 34Head and Neck Neoplasms 33Pancreatic Neoplasms 32Rectal Neoplasms 30Lymphoma, Large B-Cell, Diffuse 30Colonic Neoplasms 29

Interventions

capivasertib 2Fulvestrant 2ribociclib 1palbociclib 1abemaciclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Locally Advanced (Inoperable) or Metastatic Breast Cancer × 1 year × Clear all
NCT04862663 2026-05-27

CAPItello-292

AstraZeneca

Phase 3 Recruiting
895 enrolled
Breast

Locally Advanced (Inoperable) or Metastatic Breast Cancer

NCT04305496 2026-04-30

CAPItello-291

AstraZeneca

Phase 3 Active not recruiting
818 enrolled 19 charts 2 FDA
Breast

Locally Advanced (Inoperable) or Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡